Press coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8734487934151 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded up $0.05 during midday trading on Wednesday, hitting $1.67. 190,100 shares of the stock were exchanged, compared to its average volume of 990,664. Catabasis Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The business had revenue of $0.25 million during the quarter. sell-side analysts anticipate that Catabasis Pharmaceuticals will post -1.41 EPS for the current fiscal year.

Several equities analysts have issued reports on CATB shares. CIBC reaffirmed an “outperform” rating and set a $7.00 price objective (up from $4.00) on shares of Catabasis Pharmaceuticals in a report on Thursday, October 5th. Zacks Investment Research raised shares of Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Thursday, November 16th. Oppenheimer increased their price objective on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a report on Thursday, October 5th. Citigroup reiterated a “hold” rating and issued a $1.50 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. Finally, Cowen reiterated a “market perform” rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $4.82.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with's FREE daily email newsletter.